Opportunity Information: Apply for RFA DK 18 023
The grant opportunity titled "Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)" is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding announcement focused on accelerating practical, technology-driven advances that can make cell replacement therapies for type 1 diabetes (T1D) work better. It supports research and development aimed at creating new or improved tools, platforms, biomaterials, and devices that address key bottlenecks in replacing insulin-producing cells, with an emphasis on engineering and translational solutions rather than basic discovery alone. As indicated by the R43/R44 mechanism, the program is structured for small businesses and typically aligns with phased SBIR development, moving from early feasibility and proof-of-concept work toward more advanced development and validation as the project matures.
The scientific goal of the announcement is to improve cell replacement interventions for T1D by advancing "novel and supportive technologies." In practical terms, this points to efforts that can enhance the survival, function, and long-term performance of transplanted or implanted insulin-producing cells, as well as the methods used to deliver and protect those cells in the body. The description highlights technologies that involve novel methods, biomaterials, and devices. That framing strongly suggests interest in bioengineering approaches such as advanced cell encapsulation or immunoprotective barriers, implantable devices that improve oxygenation and nutrient transport, scaffolds or matrices that promote cell engraftment, improved manufacturing and handling approaches that preserve cell quality, and other enabling technologies that make cell replacement more reliable, durable, and scalable. The announcement is oriented toward product-enabling R and D that a small business could ultimately translate into a deployable technology supporting T1D cell therapy strategies.
This FOA is explicitly marked "Clinical Trial Not Allowed," meaning applicants are not permitted to propose or conduct clinical trials under this specific funding opportunity. Projects can still be translational and may involve preclinical development and testing, but the work must stop short of clinical trial activities as defined by NIH policy. In effect, the program supports the kind of preclinical engineering, prototyping, optimization, and validation work needed to de-risk a technology so it could later move toward clinical evaluation under other mechanisms or funding opportunities.
Eligibility is limited to small businesses, consistent with SBIR requirements. Non-domestic (non-U.S.) entities, including foreign institutions, are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply as part of the applicant organization. However, the announcement notes that "foreign components" may be allowed as defined by the NIH Grants Policy Statement, which generally refers to discrete project elements performed outside the United States under specific justifications and approvals. The practical takeaway is that the applicant organization must be an eligible U.S. small business, and any foreign involvement would need to be handled, justified, and structured in a way consistent with NIH foreign component rules rather than as a foreign applicant or a non-U.S. organizational component.
From an administrative standpoint, the opportunity is a discretionary grant under the NIH, listed under CFDA 93.847, and categorized under health-related research activities (also tagged under food and nutrition, health). The funding opportunity number is RFA-DK-18-023, and the original closing date listed is March 21, 2019, with a creation date of January 18, 2019. The source data does not provide an award ceiling or the expected number of awards, so the precise funding size and award count are not specified in the provided excerpt and would normally be confirmed in the full FOA text on NIH systems.
Overall, this program was designed to push forward enabling bioengineering technologies that can strengthen the real-world feasibility of cell replacement therapies for type 1 diabetes, with SBIR-style emphasis on innovation, development milestones, and potential commercialization pathways, while keeping the scope firmly in the preclinical or non-clinical-trial domain.Apply for RFA DK 18 023
- The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2019-01-18.
- Applicants must submit their applications by 2019-03-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The funding opportunity is titled "Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)."
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity offered under the NIH Small Business Innovation Research (SBIR) program.
What is the main purpose of this SBIR funding announcement?
The purpose is to accelerate practical, technology-driven research and development that can make cell replacement therapies for type 1 diabetes (T1D) work better by addressing key technical bottlenecks (for example, survival, function, and long-term performance of insulin-producing cells, and how those cells are delivered and protected in the body).
What kinds of projects are a good fit for this FOA?
Projects focused on new or improved tools, platforms, biomaterials, and devices that enable or improve T1D cell replacement interventions. The emphasis is on engineering and translational solutions rather than basic discovery alone.
What technology areas does the announcement appear to prioritize?
Based on the description, the FOA strongly points toward bioengineering approaches such as novel biomaterials and devices that improve transplanted or implanted cell survival and function, methods that support delivery and protection of insulin-producing cells, and other enabling technologies that improve reliability, durability, and scalability of cell replacement strategies.
Are biomaterials and device concepts within scope?
Yes. The description explicitly highlights technologies involving novel methods, biomaterials, and devices intended to support cell replacement interventions for T1D.
Is this opportunity focused on basic research or product-enabling development?
It is oriented toward product-enabling research and development a small business could ultimately translate into a deployable technology supporting T1D cell therapy strategies, rather than basic discovery alone.
What does the R43/R44 mechanism mean in this context?
R43/R44 indicates an SBIR structure that typically supports phased development, moving from early feasibility and proof-of-concept work toward more advanced development and validation as the project matures.
Are clinical trials allowed under this FOA?
No. This FOA is explicitly marked "Clinical Trial Not Allowed," meaning applicants may not propose or conduct clinical trials under this specific funding opportunity.
If clinical trials are not allowed, what types of studies can still be included?
The FOA can still support translational work, including preclinical development and testing, such as engineering, prototyping, optimization, and validation activities that de-risk a technology. The work must stop short of NIH-defined clinical trial activities.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR requirements.
Can a non-U.S. (foreign) company apply?
No. Non-domestic (non-U.S.) entities, including foreign institutions, are not eligible to apply.
Can a U.S. small business include a non-domestic component as part of the applicant organization?
No. Non-domestic components of U.S. organizations are not eligible to apply as part of the applicant organization.
Are any types of foreign involvement permitted at all?
The announcement notes that "foreign components" may be allowed as defined by the NIH Grants Policy Statement. In practice, this generally means discrete elements of the project performed outside the United States may be possible with appropriate justification and approvals, while the applicant must remain an eligible U.S. small business.
What is the funding opportunity number?
The funding opportunity number is RFA-DK-18-023.
What is the CFDA number associated with this grant?
The opportunity is listed under CFDA 93.847.
How is this grant categorized?
It is categorized under health-related research activities and is also tagged under food and nutrition and health.
What type of award is this?
It is a discretionary grant under NIH.
When was this opportunity created?
The creation date listed is January 18, 2019.
What was the closing date listed for the opportunity?
The original closing date listed is March 21, 2019.
How much funding is available per award?
The provided information does not include an award ceiling, so the specific funding size is not specified in the excerpt provided.
How many awards will be made?
The provided information does not state the expected number of awards, so the award count is not specified in the excerpt provided.
What is the overall scientific goal of the FOA?
The goal is to improve cell replacement interventions for type 1 diabetes by advancing novel and supportive technologies that improve survival, function, and long-term performance of insulin-producing cells and improve methods used to deliver and protect those cells in the body.
What is the intended impact for T1D cell replacement therapies?
The intended impact is to strengthen real-world feasibility of cell replacement therapies by removing practical bottlenecks and enabling more reliable, durable, and scalable approaches through engineering-driven innovations.
Does the FOA emphasize commercialization potential?
Yes. The description aligns with SBIR-style innovation and development milestones and highlights technology development that a small business could translate toward deployable solutions, which implies a commercialization-oriented pathway.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: National Employer Policy, Research, and Technical Assistance Center on the Employment of People with Disabilities
Previous opportunity: Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Coordinating Center (DMACC) (U24 Clinical Trials Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 18 023
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 18 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Establishing a Cohort to Clarify Risk and Protective Factors for Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) - Planning Cooperative Agreements (U34 Clinical Trial Not Allowed) Apply for RFA DK 18 007 Funding Number: RFA DK 18 007 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $225,000 |
| Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed) Apply for RFA DK 19 001 Funding Number: RFA DK 19 001 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| The KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) Apply for RFA DK 18 024 Funding Number: RFA DK 18 024 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Developmental Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Not Allowed) Apply for RFA DK 18 028 Funding Number: RFA DK 18 028 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $200,000 |
| George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional) Apply for RFA DK 18 029 Funding Number: RFA DK 18 029 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional) Apply for RFA DK 18 027 Funding Number: RFA DK 18 027 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) Apply for PAR 19 202 Funding Number: PAR 19 202 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) Data Coordinating Center (U01 Clinical Trial Not Allowed) Apply for RFA DK 19 501 Funding Number: RFA DK 19 501 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) Apply for PAR 19 222 Funding Number: PAR 19 222 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $125,000 |
| Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) Apply for RFA DK 19 003 Funding Number: RFA DK 19 003 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional) Apply for PAS 19 241 Funding Number: PAS 19 241 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional) Apply for RFA DK 19 008 Funding Number: RFA DK 19 008 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) Apply for PAR 19 294 Funding Number: PAR 19 294 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Polycystic Kidney Disease Research and Translation Core Centers (U54 Clinical Trial Not Allowed) Apply for RFA DK 19 010 Funding Number: RFA DK 19 010 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| Central Coordinating Site for the Polycystic Kidney Disease Research and Translation Core Centers (U24 Clinical Trial Not Allowed) Apply for RFA DK 19 011 Funding Number: RFA DK 19 011 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed) Apply for PAR 19 319 Funding Number: PAR 19 319 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed Apply for PAR 19 333 Funding Number: PAR 19 333 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional) Apply for RFA DK 19 019 Funding Number: RFA DK 19 019 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Clinical Research Centers (U01 Clinical Trial Optional) Apply for RFA DK 19 015 Funding Number: RFA DK 19 015 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $450,000 |
| Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Scientific and Data Coordinating Center (U24 Clinical Trial Optional) Apply for RFA DK 19 016 Funding Number: RFA DK 19 016 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 18 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.